Abstract

This method for producing fine particles includes: a step for forming a polyion complex by ion-bonding an ionic active material and an ionic polymer; and a step for forming fine particles which contain the polyion complex and at least one polymer (P) that is selected from among a polylactic acid and a lactic acid-glycolic acid copolymer. The step for forming fine particles includes: a step for mixing the polyion complex and the polymer (P) in an organic solvent; a step for forming an o/w emulsion by adding the organic solvent after mixing, the organic solvent containing the polyion complex and the polymer (P), to an aqueous solution in which a dispersant for preventing bonding between emulsions is dissolved; and a step for removing the organic solvent from the aqueous solution that contains the o/w emulsion.

IPC Classes  ?

• C08J 3/16 - Powdering or granulating by coagulating dispersions

Abstract

The present disclosure provides a method to determine whether or not a patient has received administration of a direct oral anticoagulant (DOAC). The present disclosure provides a method comprising allowing magnetic particles in a reagent to move after the addition of a sample to a dry reagent containing magnetic particles, monitoring the movement signal of the magnetic particles, analyzing the monitored movement signal of the magnetic particles, and comparing the results of analysis with a threshold, and a program and an apparatus used for such method.

IPC Classes  ?

• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

A draw solution contains a polymeric compound produced using, as starting materials, a compound represented by general formula (a) and a compound represented by general formula (b) as a draw solute. A draw solution contains a polymeric compound produced using, as starting materials, a compound represented by general formula (a) and a compound represented by general formula (b) as a draw solute. [In formula (a) and formula (b), R1 and R2 each independently represent a hydrogen atom or a methyl group.]

IPC Classes  ?

• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis
• C08F 226/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen

Abstract

[Problem] To provide a highly efficient mucosal adjuvant that can be safely administered to humans. [Solution] A mucosal adjuvant comprises bioapatite and is characterized in that low-sulfate bioapatite using calcined eggshells is included and that the antigenicity of solid membrane vesicles secreted by Streptococcus mutans is enhanced by the low-sulfate bioapatite. With this configuration, the low-sulfate bioapatite, being a component of bones and teeth, can be safely administered to humans and is easily taken up by dendritic cells, which are antigen-presenting cells, due to the very small particle size of approximately 20 nm, thereby providing a highly efficient mucosal adjuvant.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 35/74 - Bacteria
• A61K 47/02 - Inorganic compounds
• A61P 37/04 - Immunostimulants

Abstract

The present invention provides an ultrasonic vibration generation device the total length of which can be freely adjusted. An ultrasonic vibration body (3) comprises: a vibrator connection part (4) to which a vibrator unit (2) is connected; a conical horn (5) for converting at least a part of vertical vibration transmitted via the vibrator connection part 4 into lateral vibration having mutually different directions and sizes; and a columnar vibration part (6) which is provided so as to protrude from the conical horn (5) with the root thereof connected to the conical horn (5), and in which the tip is ultrasonically vibrated in a plane orthogonal to the traveling direction of the vertical vibration as the lateral vibration is transmitted.

IPC Classes  ?

• B06B 1/02 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy

Abstract

An ultrasonic projection device for projecting ultrasonic waves includes a first block body, a second block body, and a piezoelectric unit sandwiched between the first block body and the second block body. A vibration plate is provided at one end on the first block body side in the axial direction of the first block body, the second block body, and the piezoelectric unit. The dimension from the one end to the other end on the second block body side in the axial direction approximately coincides with half of the wavelength of vibration generated by the piezoelectric unit. A connection portion having a groove with a smooth inner wall surface which connects the vibration plate and a base portion is provided between the vibration plate and the base portion which supports the vibration plate.

IPC Classes  ?

• G10K 9/122 - Devices in which sound is produced by vibrating a diaphragm or analogous element, e.g. fog horns, vehicle hooters or buzzers electrically operated using piezoelectric driving means

Abstract

A composition for absorbing carbon dioxide including an ionic liquid (A) containing a cation and an anion, and a protic compound (B) having a relative permittivity at 25° C. of 20 or more, wherein the cation at least includes a cation represented by the formula (1), the anion includes an anion where an acid dissociation constant (pKa) at 25° C. of its conjugate acid in water is 4.5 or more, and the ratio of a value obtained by multiplying the number of hydroxyl groups of the protic compound (B) by the number of moles of the protic compound (B) to the number of moles of the ionic liquid (A) [number of moles of protic compound (B)/number of moles of ionic liquid (A)] is 0.2 to 1.0: A composition for absorbing carbon dioxide including an ionic liquid (A) containing a cation and an anion, and a protic compound (B) having a relative permittivity at 25° C. of 20 or more, wherein the cation at least includes a cation represented by the formula (1), the anion includes an anion where an acid dissociation constant (pKa) at 25° C. of its conjugate acid in water is 4.5 or more, and the ratio of a value obtained by multiplying the number of hydroxyl groups of the protic compound (B) by the number of moles of the protic compound (B) to the number of moles of the ionic liquid (A) [number of moles of protic compound (B)/number of moles of ionic liquid (A)] is 0.2 to 1.0: A composition for absorbing carbon dioxide including an ionic liquid (A) containing a cation and an anion, and a protic compound (B) having a relative permittivity at 25° C. of 20 or more, wherein the cation at least includes a cation represented by the formula (1), the anion includes an anion where an acid dissociation constant (pKa) at 25° C. of its conjugate acid in water is 4.5 or more, and the ratio of a value obtained by multiplying the number of hydroxyl groups of the protic compound (B) by the number of moles of the protic compound (B) to the number of moles of the ionic liquid (A) [number of moles of protic compound (B)/number of moles of ionic liquid (A)] is 0.2 to 1.0: wherein R1 and R2 each independently represent a hydrogen or a C1-C6 linear alkyl group.

IPC Classes  ?

• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption

Abstract

Eyedrops for ameliorating retinal circulation disorder and retinal neurovascular coupling disorder, the eyedrops containing fibrate-containing nanoparticles.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61P 27/02 - Ophthalmic agents

Abstract

This pain determination device comprises: a first response data acquisition unit that acquires first response data including a combination of responses by a first patient to first questions about at least one of the type of sensation of a pain which is somatic pain, the intensity of the pain, the frequency of the pain, or triggers of the pain, and responses about the first patient to second questions about at least one of psychological factors, social factors, health status, or lifestyle; and a determination unit that, on the basis of a trained model trained on the relationship between second response data, including a combination of responses by a second patient to the first questions and responses about the second patient to the second questions, and the type of cause of the pain of the second patient, determines at least one of the type of the cause of the pain of the first patient from the first response data acquired by the first response data acquisition unit, or the degree of importance of each explanatory variable, included in the first response data, to the type of the cause of the pain of the first patient.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

The present invention provides a novel method and kit for predicting the efficacy of treatment with an immunotherapeutic agent on a patient with a mucosal lesion. The present invention is a method for predicting the efficacy of treatment with an immunotherapeutic agent on a patient with a mucosal lesion, the method comprising a step for measuring the expression level of CD86 in a biological sample derived from a patient with a mucosal lesion. The present invention is a kit for use in the above method, the kit comprising a substance that binds specifically to CD86, or forward and reverse primers for amplifying nucleic acids encoding CD86.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention addresses the problem of providing a novel pharmaceutical composition for preventing proliferative vitreoretinopathy. The present invention solves the problem by providing a pharmaceutical composition for preventing proliferative vitreoretinopathy, comprising an autotaxin aptamer or a salt thereof.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 31/7125 - Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 27/02 - Ophthalmic agents
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith

Abstract

22222-E) for performing the latter step.

IPC Classes  ?

• C25B 1/23 - Carbon monoxide or syngas
• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• C25B 9/00 - Cells or assemblies of cellsConstructional parts of cellsAssemblies of constructional parts, e.g. electrode-diaphragm assembliesProcess-related cell features
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes

Abstract

This diagnosis assistance device accepts myocardial ischemia automatic quantitative values, and cardiac function information and phase information acquired by implementing cardiac stress scintigraphy; and, on the basis of the myocardial ischemia automatic quantitative values, the cardiac function information, the phase information, and a trained model, the diagnosis assistance device acquires and outputs at least one from among a reperfusion therapy prediction result, a heart failure onset prediction result, a cardiac death prediction result, a total mortality prediction result, and a coronary artery disease prediction result. The trained model is obtained by training the model with the relationship between: a combination of myocardial ischemia automatic quantitative values, cardiac function information, and phase information; and at least one from among the reperfusion therapy result, the heart failure onset prediction result, the cardiac death prediction result, the total mortality prediction result, and the coronary artery disease prediction result.

IPC Classes  ?

• G01T 1/164 - Scintigraphy
• G01T 1/161 - Applications in the field of nuclear medicine, e.g. in vivo counting
• G06T 7/00 - Image analysis

Abstract

A stable isotope-labeled indole carboxylic acid compound represented by Formula (I) is provided. In Formula (I), X1 to X8 are each independently C or 13C; Y is N or 15N; M is H, Na, K, Li, CH3, or C2H5; R1 is H or D; R2 is H, CH3, 13CH3, C2H5, or 13C2H5; R3 is H, CH3, 13CH3, C2H5, or 13C2H5; R4 is H or D; and R5 is H or D. A stable isotope-labeled indole carboxylic acid compound represented by Formula (I) is provided. In Formula (I), X1 to X8 are each independently C or 13C; Y is N or 15N; M is H, Na, K, Li, CH3, or C2H5; R1 is H or D; R2 is H, CH3, 13CH3, C2H5, or 13C2H5; R3 is H, CH3, 13CH3, C2H5, or 13C2H5; R4 is H or D; and R5 is H or D.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• G01N 33/96 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood or serum control standard

Abstract

Provided are: a simple and highly accurate sample test method which can be applied to the evaluation of the presence or absence of at least one selected from the group consisting of a gynecological cancer and a precancerous lesion thereof, the evaluation of the prognosis of a gynecological cancer patient, or the evaluation of the degree of malignancy of a gynecological cancer; a test kit which can be used for the test method; and a medicine for treating or preventing a gynecological cancer, which is intended to be administered to a subject detected by the test method. A sample test method is employed, the method comprising a step (A) for measuring the concentration of a free fatty acid in a sample from a subject and a step (B) for evaluating the possibility that the subject would have a of gynecological cancer on the basis of the concentration of the free fatty acid obtained in the step (A).

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol

Abstract

In this three-dimensional printing apparatus, a print material (F) supplied from a nozzle (64) is arranged along a print path to form a sheet-like material layer (FL) composed of a single layer or a plurality of layers. The material layer (FL) is compressed by a heating member (81) as a table (3) and the heating member (81) move relative to each other.

IPC Classes  ?

• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B29C 64/188 - Processes of additive manufacturing involving additional operations performed on the added layers, e.g. smoothing, grinding or thickness control
• B29C 64/218 - Rollers
• B29C 64/295 - Heating elements
• B29C 64/393 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

A method for producing an acidic gas absorbent containing a compound represented by general formula (1), the method comprising a step for mixing: a composition mixture of an acidic gas and a compound represented by general formula (1); and at least one protic solvent selected from the group consisting of water and alcohols having 1-3 carbon atoms and optionally having a substituent group. [In general formula (1), R1-R4each independently represent a hydrogen atom or an alkyl group having 1-6 carbon atoms, and X- represents an anion of a saturated aliphatic monocarboxylic acid having 2-6 carbon atoms.]

IPC Classes  ?

• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• C01B 32/50 - Carbon dioxide

Abstract

This method for producing human dedifferentiated fat cells comprises a step for culturing human mature fat cells using a culture medium containing human platelet lysate. This culture medium for producing human dedifferentiated fat cells from human mature fat cells contains human platelet lysate.

IPC Classes  ?

• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

This quantum tomographic imaging device, which uses an optical element having a quantum pulse gate characteristic to acquire tomographic image information at a desired depth in a biological sample: emits a probe light pulse onto the biological sample and acquires a reflected light pulse thereof; includes a delay unit for imparting a delay to a pulse for pump light, and a waveform shaping unit for performing waveform shaping of the pulse for pump light; generates a pump light pulse as a result of the delay and the waveform shaping; combines the reflected light pulse and the pump light pulse to generate a combined light pulse thereof; inputs the combined light pulse into the optical element; and, by utilizing a quantum pulse gate characteristic of the optical element, employs a single-photon detector to detect an upward converted signal light pulse obtained as a result of an upward conversion of a frequency of a desired signal light pulse contained in the combined light pulse.

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• G01B 11/24 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures
• G01J 11/00 - Measuring the characteristics of individual optical pulses or of optical pulse trains

Abstract

This ultrasonic projection device 1 for projecting ultrasonic waves comprises a first block body 2, a second block body 3, and a piezoelectric unit 4 clamped by the first block body 2 and the second block body 3. A vibration plate 6b is provided on one end on the first block body 2 side in the axial direction of the first block body 2, the second block body 3, and the piezoelectric unit 4. The dimension from the one end in the axial direction to the other end on the second block body 3 side is formed so as to approximately equal to a half wavelength of the vibration generated by the piezoelectric unit 4. A connection part 6c, in which a groove part 6e having a smooth inner wall surface 6e1 that connects the vibration plate 6b and the base part 6a is formed, is provided between the vibration plate 6b and a base part 6a that supports the vibration plate 6b.

IPC Classes  ?

• H04R 17/10 - Resonant transducers, i.e. adapted to produce maximum output at a predetermined frequency
• B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction

Abstract

For the purpose of providing a draw solution containing an UCST-type polymeric compound useful as a draw solute in a forward osmosis membrane separation method for performing the membrane separation of water using a forward osmosis membrane, a water treatment method and a water treatment apparatus, the draw solution contains a polymeric compound produced using, as starting materials, a compound represented by general formula (a) and a compound represented by general formula (b) as a draw solute. [In formula (a) and formula (b), R1and R2 each independently represent a hydrogen atom or a methyl group.]

IPC Classes  ?

• B01D 61/00 - Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltrationApparatus, accessories or auxiliary operations specially adapted therefor
• C08F 220/42 - Nitriles
• C08F 220/56 - AcrylamideMethacrylamide
• C02F 1/44 - Treatment of water, waste water, or sewage by dialysis, osmosis or reverse osmosis

Abstract

The purpose of the present invention is to provide a means for inhibiting intestinal absorption of β-alanine.　This problem can be solved by the β-alanine absorption inhibitor of the present invention that comprises, as an active ingredient, a compound selected from the group consisting of γ-aminobutyric acid, taurine, glycine, lysophosphatidylcholine and α-glycerophosphocholine, or a salt thereof.

IPC Classes  ?

• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

[Problem] To provide: a fabric-reinforced thermoplastic resin sheet molded article in which a corner part is not extremely thinned or bored, a curved part has a beautiful finished feeling without a disorder of fabric arrangement appearing on a surface of the molded article, and a fabric-reinforced thermoplastic resin sheet does not cause interlayer delamination during molding; and a manufacturing method for efficiently manufacturing the molded article. [Solution] Provided are: a method for manufacturing a fabric-reinforced thermoplastic resin sheet molded article characterized in that a fabric-reinforced thermoplastic resin sheet is vacuum-molded using a molding die having countless micropores produced by a thermally melting lamination method (3D printer) as a female die or a male die or as a female die and a male die; and a fabric-reinforced thermoplastic resin sheet molded article obtained by vacuum-molding a fabric-reinforced thermoplastic resin sheet and characterized by using a molding die having countless micropores produced by a thermally melting lamination method that is one of molding dies for vacuum molding as a female die or a male die or as a female die and a male die.

IPC Classes  ?

• B29C 51/08 - Deep-drawing or matched-mould forming, i.e. using mechanical means only
• B29C 51/14 - Shaping by thermoforming, e.g. shaping sheets in matched moulds or by deep-drawingApparatus therefor using multilayered preforms or sheets
• B29C 51/30 - Moulds
• B29K 101/12 - Thermoplastic materials
• B29K 105/08 - Condition, form or state of moulded material containing reinforcements, fillers or inserts of continuous length, e.g. cords, rovings, mats, fabrics, strands or yarns
• B33Y 10/00 - Processes of additive manufacturing
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B29C 33/38 - Moulds or coresDetails thereof or accessories therefor characterised by the material or the manufacturing process
• B29C 70/22 - Fibrous reinforcements only characterised by the structure of fibrous reinforcements using fibres of substantial or continuous length oriented in at least two directions forming a two dimensional structure
• B29C 70/42 - Shaping or impregnating by compression for producing articles of definite length, i.e. discrete articles

Abstract

A composition for carbon dioxide absorption comprising an ionic liquid (A) comprising one or more cations and an anion and a protonic compound (B) having a relative permittivity at 25°C of 20 or greater, wherein at least one of the cations is represented by general formula (1), the anion is one, the conjugate acid of which has an acid dissociation constant (pKa) in water at 25 degrees of 4.5 or greater, and the proportion of the number of moles of the protonic compound (B) multiplied by the number of hydroxyl groups of the protonic compound (B) to the number of moles of the ionic liquid (A), (number of moles of the protonic compound (B))/(number of moles of the ionic liquid (A)), is 0.2-1.0. [In general formula (1), R1and R2 each independently represent a hydrogen atom or a C1-C6 chain alkyl group.]

IPC Classes  ?

• B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• C01B 32/50 - Carbon dioxide

Abstract

An information processing device comprising: a first generation unit that uses waveforms for waves indicating changes in track displacement between a start point on a first track traveled by rolling stock to an end point on the first track, using the waveforms as track displacement waveforms, and generates a plurality of track displacement waveforms that are different from each other; a second generation unit that generates a vibration waveform, being a waveform for a wave that indicates the change in vibration expected to be generated between the start point and the end point, in a rolling stock that travels virtually along the first track, when the shape of a waveform indicating track displacement on the first track from the start point to the end point does not match the waveform indicated by the track displacement waveform, generating same for each of the plurality of track displacement waveforms generated by the first generation unit; and a third generation unit that generates correspondence information that indicates the correlation between the size of the track displacement and the size of the vibration, on the basis of the plurality of track displacement waveforms generated by the first generation unit and the vibration waveforms generated by the second generation unit for each of the plurality of track displacements.

IPC Classes  ?

• B61L 25/02 - Indicating or recording positions or identities of vehicles or trains
• G01M 17/08 - Railway vehicles

Abstract

Provided are novel determination techniques and systems enabling an AI process in which decisions are made from the viewpoint of allowing an expert to make a decision, and capable of providing a valid answer, even with a small amount of learning data, by adjusting errors in both the answer of the expert and the answer of AI. A system is configured to cause an AI process to be performed on subject teacher data for AI learning in which events of objects identified by identifying codes are divided into classes, and data pertaining to an object for which class determination of an event is required, and to receive class determination data obtained by the AI process. The system is configured to: cause teacher data for learning to be randomly input to, and learned by, each of a plurality of AI processes; input data pertaining to the object into each of the plurality of AI processes; receive from each AI process class determination data corresponding to each learning; and store the class determination data in a storage device. In this way, the class of an event of an object identified by each identifying code is determined on the basis of each class determination data item corresponding to the identifying code.

IPC Classes  ?

• G06N 20/00 - Machine learning

Abstract

A plasmid transfection agent that comprises a peptide containing an amino acid sequence represented by SEQ ID NO: 1.　SEQ ID NO: 1: CXDXXXXYXC (wherein: X represents an arbitrary amino acid residue; C represents cysteine; D represents aspartic acid; and Y represents tyrosine.)

IPC Classes  ?

• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• A61P 31/12 - Antivirals
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 19/00 - Hybrid peptides
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

The present invention has an object of providing a composition that is effective for the treatment of a prototheca disease. According to the present invention, a composition containing ravuconazole as an active ingredient, which is administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii, is provided.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 31/10 - Antimycotics
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate

Abstract

A panoramic X-ray imaging apparatus includes: an X-ray generating unit; an X-ray detecting unit; a support that supports the X-ray generating unit and the X-ray detecting unit; a drive mechanism that turns at least the X-ray generating unit and the X-ray detecting unit by driving the support; a displacement mechanism that adds movement including a displacement component in a direction different from the turning to the X-ray detecting unit; a subject holding unit that holds an imaging subject; a turning controller that controls the turning by a drive mechanism and the displacement mechanism. The turning controller controls the drive mechanism and the displacement mechanism so as to add the movement avoiding the contact with the shoulder of the imaging subject during the turning of the X-ray generating unit and the X-ray detecting unit by the drive mechanism during the panoramic X-ray imaging.

IPC Classes  ?

• A61B 6/14 - Applications or adaptations for dentistry
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/40 - Arrangements for generating radiation specially adapted for radiation diagnosis
• A61B 6/42 - Arrangements for detecting radiation specially adapted for radiation diagnosis

Abstract

The problem to be solved is to provide a new method and system for appropriately detecting a joint state from an acoustic of a joint. The present method comprises the step of obtaining, using a bio-acoustic sensor, an acoustic signal emitted by a joint during a time period that at least includes a first motion period wherein the joint changes from a first state to a second state, a pause period of the joint and a second motion period wherein the joint changes from the second state to the first state, the step of converting the obtained acoustic signal into time trend data that at least shows a relationship between an acoustic signal intensity and time, and the step of setting, from the time trend data, a basic threshold value regarding the acoustic signal intensity to calculate first acoustic information based on the basic threshold value, characterized in that the first acoustic information is an indicator of the joint state.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• H04R 1/46 - Special adaptations for use as contact microphones, e.g. on musical instrument, on stethoscope
• A61B 7/00 - Instruments for auscultation
• A61B 5/107 - Measuring physical dimensions, e.g. size of the entire body or parts thereof

Abstract

A jaw movement analysis system includes circuitry that is configured to acquire chewing information including time-series information that represents a jaw movement of a user chewing a bite of food, and to determine an attribute of the food having been chewed by the user based on the chewing information acquired and based on an analysis model. The analysis model is generated by machine learning based on training data including first information that includes time-series information indicating a past jaw movement during a chewing of a bite of food, and second information that indicates an attribute of the food chewed during the past jaw movement associated with the first information.

IPC Classes  ?

• A61C 19/045 - Measuring instruments specially adapted for dentistry for recording mandibular movement, e.g. face bows
• A61B 5/22 - ErgometryMeasuring muscular strength or the force of a muscular blow

Abstract

The purpose of the present invention is to provide a modified milk protein that has high solubility in an acidic region, excellent foaming properties and high safety, and a method for producing the milk protein while minimizing the risk of exposure to hydrolysis. This purpose can be solved by, for example, a method for producing deamidated casein that comprises a step for subjecting a casein-containing suspension to a deamidation reaction using a weakly acidic cation exchange resin, which has an alkali metal salt-type ion exchange group, for 4-50 hours at 40-90°C to thereby give deamidated casein having a deamidation ratio of 14% or more and less than 32%.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A23J 3/10 - Casein
• A23L 2/38 - Other non-alcoholic beverages
• C07K 1/18 - Ion-exchange chromatography

Abstract

A method of producing induced pluripotent stem cells including a step for introducing an initialization factor into somatic cells of a mammal, and culturing in a neural stem cell culture medium to obtain induced neural stem cell-like cells, and a step for cultivating said induced neural stem cell-like cells in a growth medium to obtain induced pluripotent stem cells, wherein the initialization factor contains an OCT family, a SOX family, a KLF family, a MYC family, a LIN28 family and a P53 function inhibitor.

IPC Classes  ?

• C12N 5/074 - Adult stem cells

Abstract

The present invention employs the following method for determining the tolerance of a Trichophyton fungus to a squalene epoxidase inhibitor. This method comprises: step (a) for, using genomic DNA of a target Trichophyton fungus as a template, conducting a nucleic acid amplification reaction with the use of a primer comprising the base sequence represented by SEQ ID NO: 1 and a primer comprising the base sequence represented by SEQ ID NO: 2 to obtain a squalene epoxidase gene fragment; step (b) for analyzing the base sequence of the squalene epoxidase gene fragment; and step (c) for, when a deduced amino acid sequence of the squalene epoxidase of the target Trichophyton fungus has a Leu393Phe mutation and/or a Phe397Leu mutation, then determining that the target Trichophyton fungus has tolerance to a squalene epoxidase inhibitor.

IPC Classes  ?

• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12Q 1/6869 - Methods for sequencing

Abstract

A nucleic acid detection kit including: (i) a first single-stranded circular DNA; (ii) a first oligonucleotide primer; (iii) a second single-stranded circular DNA; and (iv) a second oligonucleotide primer; wherein the first oligonucleotide primer is hound to a carrier through the 5′-end thereof, and the second oligonucleotide primer is bound, through the 5′-end thereof, to the carrier to which the first oligonucleotide primer is hound.

IPC Classes  ?

• C12Q 1/682 - Signal amplification
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C07D 277/66 - Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2

Abstract

Provided is a method for efficiently fixing carbon dioxide to concrete. The method includes: forming a gas injection hole in concrete included in a concrete structure; introducing a gas containing carbon dioxide into the gas injection hole; and after introducing the gas containing carbon dioxide, capping one end of the gas injection hole to seal the gas including carbon dioxide in the gas injection hole. The method may further include decompressing the gas injection hole before the introduction of the gas including carbon dioxide. The gas including carbon dioxide may further include water.

IPC Classes  ?

• E04C 3/20 - JoistsGirders, trusses, or truss-like structures, e.g. prefabricatedLintelsTransoms of concrete or other stone-like material, e.g. with reinforcements or tensioning members
• E04C 3/34 - ColumnsPillarsStruts of concrete or other stone-like material, with or without permanent form elements, with or without internal or external reinforcement, e.g. metal coverings
• E21D 11/10 - Lining with building materials with concrete cast in situShuttering or other equipment adapted therefor
• E04G 21/02 - Conveying or working-up concrete or similar masses able to be heaped or cast
• B28B 11/24 - Apparatus or processes for treating or working the shaped articles for curing, setting or hardening
• C04B 28/02 - Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing hydraulic cements other than calcium sulfates
• C04B 40/02 - Selection of the hardening environment
• B01D 53/62 - Carbon oxides
• B01D 53/82 - Solid phase processes with stationary reactants
• C01B 32/50 - Carbon dioxide
• B01J 19/00 - Chemical, physical or physico-chemical processes in generalTheir relevant apparatus

Abstract

Eyedrops for ameliorating retinal circulatory disturbance and disorders associated with retinal nerve blood vessels, which contains fibrate-containing nanoparticles.

IPC Classes  ?

• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 9/10 - DispersionsEmulsions
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/40 - CyclodextrinsDerivatives thereof
• A61P 27/02 - Ophthalmic agents

Abstract

cryptococcus that is resistant to triazole-based antifungal agents selected from the group consisting of fluconazole, itraconazole and voriconazole.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 31/10 - Antimycotics

Abstract

The present invention addresses the problem of providing a novel method and system for appropriately detecting joint status from joint acoustics. The present method is characterized by comprising: a step for acquiring, from a biological acoustics sensor, acoustic signals generated by a joint during periods including at least a first movement period when the joint changes from a first state to a second state, a joint resting period, and a second movement period when the joint changes from the second state to the first state; a step for converting the acquired acoustic signals to time trend data that at least shows the correlation between the acoustic signal intensity and time; and a step for setting the basic threshold value of the acoustic signal intensity from the time trend data, and calculating the first audio information on the basis of the basic threshold value.

IPC Classes  ?

• A61B 7/04 - Electric stethoscopes

Abstract

An antibody or an antigen-binding fragment thereof that binds specifically to a stabilon variant. A nucleic acid that encodes the antibody or antigen-binding fragment thereof. A vector containing the nucleic acid. A peptide capable of dissociating a stabilon variant tag fusion protein from the antibody or antigen-binding fragment. A transformant containing the nucleic acid. A kit containing the antibody or antigen-binding fragment.

IPC Classes  ?

• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/13 - Immunoglobulins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12P 21/08 - Monoclonal antibodies

Abstract

Provided is a pyrrole-imidazole polyamide that binds to the promoters of two or more genes and simultaneously controls transcription of the two or more genes. Also provided is a pharmaceutical composition comprising the pyrrole-imidazole polyamide. Also provided are: a pyrrole-imidazole polyamide that simultaneously controls transcription of HGF gene and TGF-β gene; a TGF-β gene expression inhibitor comprising the pyrrole-imidazole polyamide; and a pharmaceutical composition for treating a TGF-β-associated disease or a fibrous disease.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/787 - Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/00 - Drugs for dermatological disorders
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C08G 69/08 - Polyamides derived from amino carboxylic acids or from polyamines and polycarboxylic acids derived from amino carboxylic acids
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention addresses the problem of providing a device for more efficiently performing a nucleic acid amplification reaction using a primer fixed to a magnetic bead. The present invention provides a device for performing a nucleic acid amplification reaction in a reactor vessel accommodating a reaction reagent containing a primer oligonucleotide fixed to a magnetic bead, the device comprising: a coil that can be connected to an AC power source; and a support which is installed inside the coil and made of a thermally conductive magnetic material on which the reaction vessel can be placed, wherein the device further comprises a heater that heats the support.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6844 - Nucleic acid amplification reactions

Abstract

A magnetized plasmoid injection device including a cylindrical external electrode, a cylindrical internal electrode coaxially disposed inside the external electrode, a plasma generating gas supply unit that supplies plasma generating gas in a pulse shape between the external electrode and the internal electrode, a magnetic field generation unit that applies a magnetic field that generates magnetized plasmoid between the external electrode and the internal electrode, a power supply control unit that applies a discharge voltage between the external electrode and the internal electrode, and an impurity generation unit that contains an impurity in the magnetized plasmoid, the impurity generation unit having a cover electrode that opens to the external electrode, a thin-rod electrode that is located inside the cover electrode and is formed of an impurity, and an impurity generation power supply that applies a voltage to the cover electrode and the thin-rod electrode.

IPC Classes  ?

• H01J 37/32 - Gas-filled discharge tubes
• C23C 14/35 - Sputtering by application of a magnetic field, e.g. magnetron sputtering
• H05H 1/16 - Arrangements for confining plasma by electric or magnetic fieldsArrangements for heating plasma using applied electric and magnetic fields
• H05H 1/34 - Details, e.g. electrodes, nozzles

Abstract

There is provided with a method of treating cancer. A set of administration of a compound represented by General Formula (I) or a pharmaceutically acceptable salt thereof to a patient, at a dose such that 8 mg/kg or less of the compound represented by General Formula (I) is administered, and irradiation to the patient immediately following the administration is repeated. A total dosage of the irradiation to a cancer is 10 Gy or more.

IPC Classes  ?

• A61K 31/7032 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyl-diacylglycerides, lactobionic acid, gangliosides
• A61P 35/00 - Antineoplastic agents
• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy

Abstract

The present invention addresses the problem of providing: a premix reagent for nucleic acid amplification reactions, which makes it possible to perform a nucleic acid amplification reaction in a simple manner merely by mixing the premix reagent with a specimen; and a ready-to-use nucleic acid amplification reaction kit including the premix reagent for nucleic acid amplification reactions. A nucleic acid amplification reaction kit is provided, which comprises a reaction container and a nucleic acid amplification reaction reagent contained in the reaction container, the kit being characterized in that the reagent is a multi-layered reagent premix which is cryopreserved in a layered form comprising a first reagent layer that contains a nucleic acid polymerase, a second reagent layer that contains a primer oligonucleotide, and a film that separates the first reagent layer from the second reagent layer and is composed of a substance having a solid form at a temperature of lower than 0°C and capable of being dissolved in an aqueous solution at 0 to 35°C.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

A SARS-CoV-2 detection kit comprising (i) first single-stranded cyclic DNA which comprises a sequence that is complementary to a first site in a nucleic acid derived from a novel coronavirus SARS-CoV-2 and is composed of 10 to 30 nucleotides, a first primer binding sequence that is contiguous to the 5'-side of the sequence and is composed of 7 to 8 nucleotides, and a second single-stranded cyclic DNA binding sequence; (ii) a first oligonucleotide primer which comprises a sequence that is complementary to a second site contiguous to the 3'-side of the first site in the nucleic acid derived from the SARS-CoV-2 and is composed of 8 to 15 nucleotides, and a sequence that is contiguous to the 3'-side of the sequence, is complementary to the first primer binding site in the first single-stranded cyclic DNA and is composed of 7 to 8 nucleotides; (iii) second single-stranded cyclic DNA which comprises a sequence that is identical to the second single-stranded cyclic DNA binding sequence in the first single-stranded cyclic DNA and a second primer binding sequence that is contiguous to the 5'-side of the sequence; and (iv) a second oligonucleotide primer which comprises a sequence that is identical to a site contiguous to the 5'-side of the second single-stranded cyclic DNA binding sequence in the first single-stranded cyclic DNA and a sequence that is contiguous to the 3'-side of the sequence and is complementary to the second primer binding sequence in the second single-stranded cyclic DNA, in which the first oligonucleotide primer is bonded to a support through the 5'-terminal thereof, and the second oligonucleotide primer is bonded, through the 5'-terminlal thereof, to the support having the first oligonucleotide primer bonded thereto.

IPC Classes  ?

• C12Q 1/6844 - Nucleic acid amplification reactions
• C12N 15/50 - Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

This bone augmentation structure comprises a collagen tube and a collagen structure stored within the collagen tube. The collagen tube has a porosity of 70-98%.

IPC Classes  ?

• A61L 27/24 - Collagen
• A61C 8/00 - Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereonDental implantsImplanting tools

Abstract

This shape-memory resin composition contains: a resin (A) having a constitutional unit (a1) represented by general formula (a-1) and a constitutional unit (a2) represented by general formula (a-2); titania nanoparticles (B); and a tetraalkylphosphonium salt (C), and can be thermally melted and molded. In formula (a-1), R1is a hydrogen atom or the like. Ra1is a C1-C5 alkyl group. In formula (a-2), R2is a hydrogen atom or the like. X2is a nitrogen-containing cyclic group, a group represented by formula (a-2-1), or a group represented by formula (a-2-2). In formula (a-2-2), Ya2 is a C1-C5 alkylene group.

IPC Classes  ?

• C08F 226/06 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
• C08K 5/50 - Phosphorus bound to carbon only
• C08L 33/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
• C08J 5/00 - Manufacture of articles or shaped materials containing macromolecular substances
• C08K 3/24 - AcidsSalts thereof

Abstract

Provided are novel determination techniques and systems enabling an AI process in which decisions are made from the viewpoint of allowing an expert to make a decision, and capable of providing a valid answer, even with a small amount of learning data, by adjusting errors in both the answer of the expert and the answer of AI. A system is configured to cause an AI process to be performed on subject training data for AI learning in which events of objects identified by identifying codes are divided into classes, and data pertaining to an object for which class determination of an event is required, and to receive class determination data obtained by the AI process. The system is configured to: cause training data for learning to be randomly input to, and learned by, each of a plurality of AI processes; input data pertaining to the object into each of the plurality of AI processes; receive from each AI process class determination data corresponding to each learning; and store the class determination data in a storage device. In this way, the class of an event of an object identified by each identifying code is determined on the basis of each class determination data item corresponding to the identifying code.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 20/00 - Machine learning

Abstract

A user terminal 4 comprises: an analysis unit 42 (a chewing segment identification module 42a and a filtering/calculation module 42b) that obtains chewing information, which is chronological information indicating jaw movement for one mouthful when a user is eating; and an analysis unit 42 (analysis module 42c) that enters the chewing information to an analysis model M1 and obtains attributes for food estimated as having been chewed by a user by using jaw movement for one mouthful, output from the analysis model M1. The analysis model M1 is a trained model that has machine-learned from teaching data that includes: first information being chronological information indicating past jaw movement for one mouthful, obtained for the user; and second information indicating attributes of food chewed by the user, using past jaw movement for one mouthful.

IPC Classes  ?

• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb

Abstract

A learning model provided in a segmentation device is a learning model which is generated using training data such that segmentation data of a biologically important region is output when data of a constituent maxillofacial region is input.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G06T 7/11 - Region-based segmentation
• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/08 - Learning methods

Abstract

24244 nanoparticles of the complex is preferably 10 nm or less.

IPC Classes  ?

• C01G 51/00 - Compounds of cobalt
• C07F 9/54 - Quaternary phosphonium compounds

Abstract

A spectral image generation device comprising: a light source that outputs weak light including photons having different energy; a digital micro mirror device that reflects photons output from the light source and transmits the photons through an imaging subject, reflects photons that have passed through the imaging subject, reflects photons that have been reflected by the imaging subject, or reflects photons output from the light source towards the imaging subject; a photon detector that executes processing that detects photons that have passed through the imaging subject and processing that measures the energy of those photons or processing that detects photons reflected by the imaging subject and processing that measures the energy of those photons; and a spectral image generation unit that uses the results of the processing executed by the photon detector and generates a spectral image of the imaging subject.

IPC Classes  ?

• G01N 21/01 - Arrangements or apparatus for facilitating the optical investigation
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/64 - FluorescencePhosphorescence

Abstract

The purpose of the present invention is to provide a composition that is effective for the treatment of a prototheca disease. The present invention provides a composition characterized by containing ravuconazole as an active ingredient, and being administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 33/00 - Antiparasitic agents

Abstract

The purpose of the present invention is to provide a composition that is effective for the treatment of a prototheca disease. The present invention provides a composition characterized by containing ravuconazole as an active ingredient, and being administered to an animal suffering from a prototheca disease caused by Prototheca wickerhamii or Prototheca zopfii.

IPC Classes  ?

• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion

Abstract

Provided is a method for producing a gelatinous composition, the method including: a step for mixing lecithin that has been dissolved or dispersed in water and an organic compound (excluding lecithin) having a molecular weight of 500 or more that has been dissolved or dispersed in water to obtain a mixed liquid containing the lecithin and the organic compound; a step for freeze-drying or heat-drying the mixed liquid to obtain a solid mixture containing the lecithin and the organic compound; and a step for mixing the solid mixture, an oil component and a polar liquid to obtain a gelatinous composition. Also provided is a gelatinous composition produced using the production method.

IPC Classes  ?

• A61P 17/00 - Drugs for dermatological disorders
• A61Q 1/00 - Make-up preparationsBody powdersPreparations for removing make-up
• A61K 9/06 - OintmentsBases therefor
• A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
• A61K 8/55 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing phosphorus
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

This drug delivery composition is for the delivery of a drug to the spinal cord; comprises a membrane-permeable peptide and a block copolymer in which a polyethylene glycol segment is linked to a hydrophobic polyester segment; and is administered nasally. This pharmaceutical composition comprises the drug delivery composition and a drug for the treatment of a spinal cord disease and is administered nasally for the treatment of a spinal cord disease.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Abstract

The object of the present invention is to provide a method for determining the sensitivity of a subject to an SGLT2 inhibitor, and a sensitivity marker for the SGLT2 inhibitor. The present invention provides a method for determining the sensitivity of a subject to an SGLT2 inhibitor, comprising measuring a biomarker in the biological sample of a subject, and determining the sensitivity of the subject to the SGLT2 inhibitor using the measured biomarker value as an indicator.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

This method of producing induced pluripotent stem cells involves a step for introducing an initialization factor into somatic cells of a mammal, and culturing in a neural stem cell culture medium to obtain induced neural stem cell-like cells, and a step for cultivating said induced neural stem cell-like cells in a growth medium to obtain induced pluripotent stem cells , wherein the initialization factor contains an OCT family, a SOX family, a KLF family, a MYC family, a LIN28 family and a P53 function inhibitor.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

A nucleic acid detection kit comprising (i) a first single-stranded circular DNA, (ii) a first oligonucleotide primer, (iii) a second single-stranded circular DNA and (iv) a second oligonucleotide primer, wherein the first oligonucleotide primer is attached to a carrier via the 5'-terminus thereof, and the second oligonucleotide primer is attached to the carrier, to which the first oligonucleotide primer is attached, via the 5'-terminus thereof.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6834 - Enzymatic or biochemical coupling of nucleic acids to a solid phase
• C12Q 1/6839 - Triple helix formation or other higher order conformations in hybridisation assays
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

The purpose of the present invention is to provide an anti-fungal agent effective for cryptococcosis. The present invention provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal with cryptococcosis. The present invention also provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal infected by Cryptococcus neoformans having resistance against a triazole-based antibacterial agent selected from the group consisting of fluconazole, itraconazole, and voriconazole.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 31/10 - Antimycotics

Abstract

The purpose of the present invention is to provide an anti-fungal agent effective for cryptococcosis. The present invention provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal with cryptococcosis. The present invention also provides an anti-fungal agent containing ravuconazole as an active ingredient, the anti-fungal agent being characterized by being administered to an animal infected by Cryptococcus neoformans having resistance against a triazole-based antibacterial agent selected from the group consisting of fluconazole, itraconazole, and voriconazole.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 31/10 - Antimycotics

Abstract

The present invention improves the effect of radiotherapy.　This radiosensitizer for treating cancer contains a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, the radiosensitizer being characterized by being used so that a compound represented by general formula (I) is administered to a patient in an amount of 8 mg/kg or less per dose. This radiosensitizer is also characterized by being used to repeat a set of the administration of the radiosensitizer and the irradiation with radiation immediately after the administration so that the total irradiation dose of radiation with respect to cancer is 10 Gy or greater.

IPC Classes  ?

• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention is to provide a tissue slice selection method and an embedded block-preparing cassette which are capable of suppressing occurrence of errors in inspection results. The present invention makes it possible to suppress the occurrence of errors in inspection results by including: an embedded block-preparing process of preparing an embedded block by embedding both a biological tissue fragment and a standard substance in the same embedding agent; an embedded tissue slice preparing step of slicing the embedded block to prepare a sheet-like embedded tissue slice having a tissue slice and standard substance slices appearing on a surface thereof; and a tissue slice selecting step of selecting the tissue slice to be inspected, based on a light signal from the standard substance slice.

IPC Classes  ?

• G01N 1/06 - Devices for withdrawing samples in the solid state, e.g. by cutting providing a thin slice, e.g. microtome
• G01N 1/30 - StainingImpregnating
• G01N 1/36 - Embedding or analogous mounting of samples
• G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper

Abstract

A magnetized plasmoid injection device (10) which enables the precise control of the amount of impurities, and which is provided with: a cylindrical external electrode (11); an internal electrode (12) which is coaxially arranged within the external electrode; a plasma generating gas supply unit (13) which supplies a plasma generating gas in a pulse state between the external electrode and the internal electrode; a magnetic field generation unit (15) which applies a magnetic field that generates a magnetized plasmoid between the external electrode and the internal electrode; a power supply control unit (14) which applies a discharge voltage between the external electrode and the internal electrode; and an impurity generation unit (100) which has the magnetized plasmoid contain impurities. The impurity generation unit comprises: a cover electrode (102) which opens to the external electrode; a needle-like electrode (101) which is positioned within the cover electrode, while being composed of impurities; and an impurity generating power supply which applies a voltage to the cover electrode and the needle-like electrode.

IPC Classes  ?

• H05H 1/16 - Arrangements for confining plasma by electric or magnetic fieldsArrangements for heating plasma using applied electric and magnetic fields
• H05H 1/26 - Plasma torches
• G21B 1/05 - Thermonuclear fusion reactors with magnetic or electric plasma confinement
• G21B 1/11 - Thermonuclear fusion reactors Details
• C23C 14/22 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the process of coating

Abstract

A three-dimensional printing apparatus (1) allowing a linear filament (F) in which a fiber bundle (C) is impregnated with resin (P) to be continuously ejected includes twisting means (6) for allowing a total amount of twisting of the filament (F) or an amount of twisting of the fiber bundle (C) to be changed.

IPC Classes  ?

• B29C 64/336 - Feeding of two or more materials
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B29C 64/209 - HeadsNozzles

Abstract

3 is, identically or differently in each occurrence, selected from hydrogen and an optionally substituted aliphatic hydrocarbon group; and n represents an integer of 1 or more.

IPC Classes  ?

• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Abstract

The invention provides a novel polymer, a composition, and a molded article. The polymer contains a constitutional unit represented by the following formula (1): 11 is a hydrogen atom or an alkyl group optionally containing a fluorine atom; and a is an integer of 1 to 4.

IPC Classes  ?

• C08G 77/52 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages containing aromatic rings
• C08L 27/18 - Homopolymers or copolymers of tetrafluoroethene
• C09K 3/10 - Materials not provided for elsewhere for sealing or packing joints or covers

Abstract

A compound represented by general formula (1). (In formula (1), R1-R311 -is any anion selected from Cl-, Br-, I-66 -22N-, BETI-, and TSAC-.)

IPC Classes  ?

• C07F 9/54 - Quaternary phosphonium compounds
• B01F 17/40 - Phenols
• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
• C01G 51/00 - Compounds of cobalt

Abstract

A production device 10 for fiber-reinforced thermoplastic resin comprising: an impregnation chamber for impregnating a thermoplastic resin monomer liquid or solution into a plurality of long fibers 20; a polymerization chamber 11 for polymerizing the monomer by heating the long fibers 20 that are impregnated with the monomer; and a moving unit 16 for drawing the long fibers 20 impregnated with the thermoplastic resin from the chamber.

IPC Classes  ?

• B29B 15/12 - Coating or impregnating of reinforcements of indefinite length
• C08G 69/16 - Preparatory processes
• B29K 77/00 - Use of polyamides, e.g. polyesteramides, as moulding material
• B29K 105/08 - Condition, form or state of moulded material containing reinforcements, fillers or inserts of continuous length, e.g. cords, rovings, mats, fabrics, strands or yarns

Abstract

f) is configured to receive the examination light (R) which has been transmitted through the tooth.

IPC Classes  ?

• A61B 1/24 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the mouth, i.e. stomatoscopes, e.g. with tongue depressorsInstruments for opening or keeping open the mouth
• A61C 19/04 - Measuring instruments specially adapted for dentistry
• A61B 1/07 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements using light-conductive means, e.g. optical fibres
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61C 1/08 - Machine parts specially adapted for dentistry

Abstract

A medical X-ray CT imaging apparatus includes an X-ray generator that generates a cone beam, an X-ray detector, a support that supports the X-ray generator and the X-ray detector while the X-ray generator and the X-ray detector are opposed to each other, a turning drive unit that turns the X-ray generator and the X-ray detector, which are supported by the support, an imaging information receiving unit, and an X-ray output condition setting unit. The imaging information receiving unit receives an imaging area setting relating to at least one of a size of an imaging area, an imaging purpose, and an imaging region. The X-ray output condition setting unit automatically sets an output condition of the X-ray generator according to at least one of the size of the imaging area, the imaging purpose, and the imaging region, which are received by the imaging information receiving unit.

IPC Classes  ?

• A61B 6/14 - Applications or adaptations for dentistry
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/03 - Computed tomography [CT]

Abstract

16117222 represents a single bond or a C1-6 linear alkylene group), An-12345611's, and two An-'s each represent the same thing.]

IPC Classes  ?

• C09B 11/28 - Pyronines
• C09B 67/20 - Preparations of organic pigments
• G02B 5/20 - Filters
• C07D 311/82 - Xanthenes

Abstract

A first position setting unit receives an operation to designate a position in a mesiodistal on a panoramic tomographic image displayed on a display, and sets a first position on a curved section based on the designation operation. The fluoroscopic imaging information providing unit provides information irradiating a subject with an X-ray beam along a direction having a component of a tangential direction at the first position of the curved section to execute fluoroscopic imaging acquiring a fluoroscopic image to a main body. A second position setting unit receives an operation to designate a position in a buccolingual direction on the fluoroscopic image displayed on the display, and sets a second position in the buccolingual direction based on the designation operation.

IPC Classes  ?

• A61B 6/14 - Applications or adaptations for dentistry
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• A61B 6/10 - Safety means specially adapted therefor
• A61B 6/03 - Computed tomography [CT]

Abstract

Provided are a tissue slice selection method and an embedded block preparing cassette with which it is possible to suppress the occurrence of errors in inspection results. This tissue slice selection method makes it possible to suppress the occurrence of errors in inspection results by comprising: an embedded block preparing step of preparing an embedded block 24 by embedding a biological tissue piece 22 and a reference material 21 in the same embedding agent 23; an embedded tissue slice preparing step of thinly cutting the embedded block 24 to prepare a sheet-like embedded tissue slice 44 in the surface of which a tissue slice 42 and a reference material slice 41a, 41b, 41c, 41d, 41e appear; and a tissue slice selecting step of selecting the tissue slice 42 to be inspected, on the basis of an optical signal from the reference material slice.

IPC Classes  ?

• G01N 1/06 - Devices for withdrawing samples in the solid state, e.g. by cutting providing a thin slice, e.g. microtome
• G01N 1/30 - StainingImpregnating
• G01N 1/36 - Embedding or analogous mounting of samples
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

Provided is a preparation which has an effect of promoting the healing of a tissue wound. The wound healing promoter according to the present invention comprises, as an active ingredient, at least one member selected from among a compound represented by formula (1), a salt thereof and a hydrate of the same. In formula (1): R1 and R2 are either the same or different and represent a hydrogen atom or a hydrocarbon group optionally having one or more substituents selected from the group consisting of a halogen atom, -COOR3, -CONR32, -COR3, -CN, -NO2, -NHCOR3, -OR3, -SR3, -OCOR3, -SO3R3 and -SO2NR32 (wherein R3's are either the same or different and represent a hydrogen atom or an optionally substituted aliphatic hydrocarbon group); and n is an integer of 1 or greater.

IPC Classes  ?

• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• A61K 9/06 - OintmentsBases therefor
• A61K 9/08 - Solutions
• A61K 9/12 - AerosolsFoams
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/68 - Medicinal preparations characterised by special physical form chewing gum type
• A61K 9/70 - Web, sheet or filament bases
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastesMouth rinses

Abstract

This score determination device of a medical examination for biological function is provided with: a weight calculation unit which calculates a weight on the basis of first data including, among data about a first subject, at least one among data that includes a determination score of a medical examination based on the subject's own report and indicates an examination result of the medical examination, and data that indicates a physical feature; and a score determination unit which determines a determination score of a second subject on the basis of the weight calculated by the weight calculation unit, and second data including, among data about the second subject, at least one among data which indicates an examination result of a medical examination and data which indicates a physical feature.

IPC Classes  ?

• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• A61B 5/026 - Measuring blood flow
• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters

Abstract

[Problem] To provide a temperature-responsive hydrogel by means of a simple method (mixing), said temperature-responsive hydrogel having a feature such that the viscosity thereof is high at high temperatures but low at low temperatures. [Solution] It is found that a temperature-responsive hydrogel which has high viscosity at high temperatures and low viscosity at low temperatures, while having a high (viscosity at high temperatures)/(viscosity at low temperatures) ratio, is able to be obtained by a method for mixing an aqueous solution containing a polyalkylene glycol (A) that has a weight average molecular weight of from 20,000 to 10,000,000 and an aqueous solution containing a silicate (B) within a specific component composition range, specifically at a mass concentration of A of 0.01-1.5% by mass, preferably at a mass concentration of A of 0.1-0.4% by mass and at a mass concentration of B of 0.5-10% by mass, preferably at a mass concentration of B of 1-5% by mass, with the mass ratio R of A to B (R = (mass of A)/(mass of B)) being within the range of from 0.01 to 0.5; and this finding led to the completion of the present invention.

IPC Classes  ?

• C08L 71/02 - Polyalkylene oxides
• A61L 31/14 - Materials characterised by their function or physical properties
• B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
• C08J 3/075 - Macromolecular gels
• C08K 3/32 - Phosphorus-containing compounds
• C08K 3/34 - Silicon-containing compounds
• C08K 5/092 - Polycarboxylic acids

Abstract

A three-dimensional printing apparatus (1) capable of continuously ejecting a linear filament (F) in which a fiber bundle (C) is impregnated with resin (P) is provided with twisting means (6) capable of changing the overall amount of twisting of the filament (F) or a twisting amount of the fiber bundle (C).

IPC Classes  ?

• B29C 64/205 - Means for applying layers
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• D02G 3/44 - Yarns or threads characterised by the purpose for which they are designed

Abstract

Conventional reverse photochromic compounds have difficulty in sensing light in a visible light region of 600 nm or more used in medical applications, etc. The present invention addresses the problem of providing a reverse photochromic compound and polymer which are highly sensitive even to light of 600 nm or more. The present invention pertains to a compound or the like represented by general formula (1) (wherein, R1 and R4 each independently represent a hydrogen atom or the like, R2, R3, and R5 each independently represent an alkyl group or the like, R6 represents a group having a polymerizable unsaturated group, a carboxy group, an alkoxycarbonyl group, or the like, R31 and R32 each independently represent an alkoxy group or the like, R33 and R34 each independently represent a hydrogen atom or the like, Y1 represents an oxygen atom or a sulfur atom, An- represents an anion, n1-n3 represent a specific integer, and R1 and R2, R3 and R4, and/or R33 and R34 may form an alkylene group.)

IPC Classes  ?

• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C08F 20/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen
• C09K 9/02 - Organic tenebrescent materials

Abstract

The present invention provides a novel polymer, a composition, and a molded article. This polymer has a structural unit represented by general formula (1) (in the formula, X11 and X12 may be the same or different from each other, and each represent a hydrogen atom, an alkyl group optionally having a fluorine atom, or a phenyl group, Y11 represents an oxygen atom or a sulfur atom, Rf11 represents a hydrogen atom or an alkyl group optionally having a fluorine atom, and a represents an integer of 1-4).

IPC Classes  ?

• C08G 77/52 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms by carbon linkages containing aromatic rings
• C08L 83/14 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen, or carbon onlyCompositions of derivatives of such polymers in which at least two but not all the silicon atoms are connected by linkages other than oxygen atoms
• C08L 101/04 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups containing halogen atoms
• C09K 3/10 - Materials not provided for elsewhere for sealing or packing joints or covers
• H01L 21/3065 - Plasma etchingReactive-ion etching

Abstract

The disease condition determination device according to the present invention is provided with: a first separation degree calculation unit for calculating a degree of separation on the basis of first load blood flow information which is blood flow information for a task state in which a first load for varying the blood flow state of a subject is imposed on the subject, and second load blood flow information which is blood flow information for a control state in which a second load different from the first load is imposed on the subject, from among blood flow information obtained by measuring blood flow in the brain of a subject by optical measurement using near-infrared rays; an oscillation detection unit for detecting oscillation in variation of the hemoglobin concentration of the blood flow of the subject on the basis of non-load blood flow information; a phase detection unit for detecting the phase of the variation in hemoglobin concentration of the blood flow of the subject on the basis of the non-load blood flow information; and a determination unit for determining the disease condition of the subject on the basis of the degree of separation calculated by the first separation degree calculation unit, the oscillation detected by the oscillation detection unit, and the phase detected by the phase detection unit.

IPC Classes  ?

• A61B 5/1455 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters
• A61B 5/026 - Measuring blood flow
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements

Abstract

A device for calculating construction assistance information includes: an acquisition unit that acquires, from a vibratory hammer construction machine, information that contains at least values indicating a eccentricity force of a vibratory hammer which the vibratory hammer construction machine imparts to a construction object, the number of impacts, and a depth of penetration of the construction object; and a calculation unit that calculates a accumulated impact force indicating a work load of construction on the basis of the information acquired by the acquisition unit.

IPC Classes  ?

• E02D 13/06 - Accessories for placing or removing piles or bulkheads for observation while placing
• E02D 7/18 - Placing by vibrating

Abstract

Provided is a therapeutic agent for periodontitis containing a Hepatocyte Growth Factor (HGF) signal inhibitor as an active ingredient.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

An oligonucleotide selected from the group consisting of the following oligonucleotides (i) to (iii): (i) an oligonucleotide which comprises the nucleotide sequence represented by SEQ ID NO: 15; (ii) an oligonucleotide which comprises a nucleotide sequence produced by deleting, substituting or adding one or several residues in the nucleotide sequence represented by SEQ ID NO: 15 and which has a binding ability specific to ITS2 of Aspergillus terreus; and (iii) an oligonucleotide which comprises a nucleotide sequence complementary to the nucleotide sequence for the oligonucleotide (i) or (ii).

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A dental caries diagnosis device comprising a light source which emits examination light (R), and a light receiving unit (4f) which receives the examination light (R) with which a tooth has been irradiated comprises: a head-side casing (4a1) which is inserted into the mouth in a contactless manner with respect to the tooth or the gum, and which projects the examination light (R) toward the tooth; and a filter (4e) which is disposed in front of the light receiving unit (4f) and which removes a noise component from the received light, wherein the light receiving unit (4f) receives the examination light (R) that has been transmitted through the tooth.

IPC Classes  ?

• A61B 1/24 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the mouth, i.e. stomatoscopes, e.g. with tongue depressorsInstruments for opening or keeping open the mouth
• A61C 19/04 - Measuring instruments specially adapted for dentistry

Abstract

Since a miRNA that serves as a diagnostic marker for periodontitis of the present invention displays a change specific to periodontitis, diagnosis of periodontitis can be performed accurately.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/09 - Recombinant DNA-technology
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

A three-dimensional printing apparatus (1) is provided with: a head (4) to which linear print material is to be fed; a driving unit that performs relative movement between the head (4) and a target surface (3a); a controller; and a pressing means (30) having a pressing surface (41) disposed to be capable of coming in contact with the print material on the target surface (3a). The pressing means (30) is configured to allow movement of the pressing surface (41) with respect to the head (4).

IPC Classes  ?

• B29C 67/00 - Shaping techniques not covered by groups , or
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor

Abstract

A three-dimensional printing system (1) includes: a head (2) to which a first continuous material (FL) including a resin and a second continuous material (FB) including fibers are fed; a platform (3) on which a printing material based on the first and second continuous materials from the head is stacked; a cutting device (10) which is capable of cutting at least fibers; and a controller (5) which controls an operation device including at least one of the head, the platform, and the cutting device.

IPC Classes  ?

• B29C 64/209 - HeadsNozzles
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes
• B33Y 80/00 - Products made by additive manufacturing
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B29C 64/118 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using filamentary material being melted, e.g. fused deposition modelling [FDM]
• B29C 64/295 - Heating elements
• B29C 70/38 - Automated lay-up, e.g. using robots, laying filaments according to predetermined patterns
• B29K 105/08 - Condition, form or state of moulded material containing reinforcements, fillers or inserts of continuous length, e.g. cords, rovings, mats, fabrics, strands or yarns

Abstract

A culture container 1 comprising a culture container body 11, a partition board 15 that is disposed in the vicinity of the bottom surface 11c of the culture container body 11 facing the bottom surface 11c and forms a culture area A1 as a culture area being positioned between the partition board 15 and the bottom surface 11c, and a sample inlet/outlet 19 that is formed in the culture container body 11, wherein the sample inlet/outlet 19 communicates with the culture area A1 via an opening formed on one end side of the partition board 15. By using the culture container 1 and a culture method using the same, a large amount of fat cells can be cultured at once by a simple operation. Thus, a large amount of fat cells can be efficiently dedifferentiated and non-dedifferentiated cells can be efficiently removed.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 3/04 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing thin layers
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells

Abstract

Seat members 31 are held in a state of being movable with respect to first slide members 21 or second slide members 22 correspondingly. By rotating screws 39 in directions to increase the distances d between surfaces A of the first slide members 21 or the second slide members 22 and surfaces B of the seat members 31, chucks 25 are moved in directions to increase the distance between the chucks to apply pretension to a test piece correspondingly. When backlash in a force transmission system from a support part to the respective chucks 25 is eliminated, a biaxial tensile test is started.

IPC Classes  ?

• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
• G01N 3/04 - Chucks

Abstract

The present invention is a labeled peptide formed from a non-naturally occurring amino acid sequence that is represented by formula (1). (XFNXN)mXp(XFNXN)nXq (1) (In formula (1), each X is independently an aspartic acid residue or a glutamic acid residue, F is a phenylalanine residue, N is an asparagine residue, m is an integer of 0 to 5, n is an integer of 1 to 5, p is an integer of 1 to 20, and q is an integer of 1 to 4.)

IPC Classes  ?

• C07K 7/04 - Linear peptides containing only normal peptide links
• C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 19/00 - Hybrid peptides
• C12N 15/09 - Recombinant DNA-technology
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

The present invention addresses the problem of providing a cell for use in a vascular regeneration therapy, which has a superior blood flow-improving effect compared with a bone marrow-derived MSC, an ASC or the like that is a conventional cell for use in a therapy, and which can be obtained easily in an amount sufficient enough for transplantation, and which has stable quality. It is found that a human DFAT has a high neovascularization ability, can exhibit a high proliferation ability after being subcultured and therefore can be produced easily in an amount needed for transplantation, and does not undergo transformation. Therefore, it is found for the first time that a human DFAT is effective for a vascular regeneration therapy for a human body. These findings lead to the accomplishment of the present invention. That is, the present invention provides a blood flow-improving agent containing human dedifferentiated fat cells (human DFAT) as an active ingredient.

IPC Classes  ?

• A61K 35/35 - Fat tissueAdipocytesStromal cellsConnective tissues
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

Established are an analysis of markers of aggressive fibroblasts which are cells that cause periodontitis, screening of novel periodontitis therapeutics, a test method, and a test kit. As a result of analyzing aggressive fibroblasts, it has become apparent that expression from the P1 promoter of RUNX2 and expression of DLX5 are decreased to a greater extent than in normal gingival fibroblasts. An increase in expression of FLT1 was also seen. Using these expressions characteristic of aggressive fibroblasts as markers makes possible the identification of aggressive fibroblasts, a method for screening therapeutics, and a test method.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12N 15/09 - Recombinant DNA-technology

Abstract

A device for calculating construction assistance information comprises: an acquiring unit that acquires, from vibratory hammer construction machinery, information that contains at least values indicating the vibratory hammer vibrating force applied to the object of construction by the vibratory hammer construction machinery, the number of impacts, and the depth of penetration of the object of construction; and a calculating unit that calculates, on the basis of the information acquired by the acquiring unit, the cumulative impact force that indicates the amount of construction work.

IPC Classes  ?

• E02D 13/06 - Accessories for placing or removing piles or bulkheads for observation while placing
• E02D 7/18 - Placing by vibrating

Abstract

A reverse ABO blood grouping test device (1) according to the present invention is provided with: a chip (2) which has a waveguide layer (6) formed therein; an antigen-immobilizing surface (10) which is formed on a first surface (2a) of the chip (2); an antigen (20) which has an immobilizing end (20a) that is immobilized onto the antigen-immobilizing surface (10) and an open end (20b) that is kept non-immobilized, and which can cause an antigen-antibody reaction with an anti-A antibody (PA) or an anti-B antibody (PB); and a determination section (40) in which it is determined whether or not an antigen-antibody reaction occurs at the antigen (20) on the basis of the wavelength distribution of the intensity of light that enters the chip (2) and is emitted through the chip (2).

IPC Classes  ?

• G01N 33/80 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood groups or blood types
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/552 - Attenuated total reflection
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/531 - Production of immunochemical test materials
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/552 - Glass or silica

Abstract

Provided is a muon-plasmoid complex nuclear fusion reactor whereby muon reactivation can be performed in order to increase the efficiency of energy production. A muon-plasmoid nuclear fusion reactor for obtaining a nuclear fusion reaction comprises a target container 10, a solid hydrogen ice fog generating source 20, a plasmoid generating source 30, and a muon generating source 40. The solid hydrogen ice fog generating source 20 is connected to the target container 10, and injects solid hydrogen into the target container 10 and forms a solid hydrogen ice fog 21. The plasmoid generating source 30 is connected to the target container 10, and generates a magnetized plasmoid 31, transports the magnetized plasmoid into the solid hydrogen ice fog 21 in the target container 10, and forms a solid-plasma complex region 32. The muon generating source 40 is connected to the target container 10, and injects muons 41 into the solid-plasma complex region 32 to obtain a nuclear reaction.

IPC Classes  ?

• G21B 3/00 - Low-temperature nuclear fusion reactors, e.g. alleged cold fusion reactors
• G21B 1/00 - Thermonuclear fusion reactors

Abstract

This vaccine for activating CD8 T-cells has an active ingredient of bacillus Calmette–Guérin (BCG) in which a protein derived from pathogenic microorganisms is expressed. The vaccine is useful due to the ability of the vaccine to activate CD8+ T-cells that are specific to an antigen derived from pathogenic microorganisms.

IPC Classes  ?

• A61K 39/04 - Mycobacterium, e.g. Mycobacterium tuberculosis
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/06 - Antibacterial agents for tuberculosis
• A61P 37/04 - Immunostimulants
• C07K 14/35 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycobacteriaceae (F)
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention is a cellular-disorder inhibitor characterized by containing any one of peptides (a) to (g), a derivative thereof, or a salt or ester of these as an active ingredient.

IPC Classes  ?

• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

A steam corrosion-resistant multilayered film formed on a base material containing a silicon carbide composite material, said steam corrosion-resistant multilayered film being characterized by comprising: an eutectic structure layer containing an eutectic structure of a plurality of metal oxides which is formed without any grain boundary glass phase existing therein; and a gradient composition layer which is interposed between the eutectic structure layer and the base material, which contains the metal oxides and metal carbides, and in which the compositional ratio of the metal carbides gradiently increases toward the base material.

IPC Classes  ?

• C04B 41/87 - Ceramics
• B32B 9/00 - Layered products essentially comprising a particular substance not covered by groups
• C04B 41/89 - Coating or impregnating for obtaining at least two superposed coatings having different compositions
• F01D 5/28 - Selecting particular materialsMeasures against erosion or corrosion